Dr. Mok Discusses Developing Lung Cancer Treatments

Tony S.K. Mok, BMSc, MD, FRCPC
Published Online: Thursday, Sep 12, 2013
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.

Mok says in order to move forward, multiple parties such as pharmaceutical industries, academic institutions, and the FDA have to make changes.

As an example, Mok says, the FDA should look into how it registers drugs because the current practice of demanding a companion diagnostic may actually be slowing down the development of the drug.

Mok also suggests making changes to the pharmaceutical industry by having external tribunals advise pharmaceutical companies on which drugs to develop rather than wasting money by trying to develop many drugs.

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.

Mok says in order to move forward, multiple parties such as pharmaceutical industries, academic institutions, and the FDA have to make changes.

As an example, Mok says, the FDA should look into how it registers drugs because the current practice of demanding a companion diagnostic may actually be slowing down the development of the drug.

Mok also suggests making changes to the pharmaceutical industry by having external tribunals advise pharmaceutical companies on which drugs to develop rather than wasting money by trying to develop many drugs.

Online CME Activities
TitleExpiration DateCME Credits
2nd Annual Miami Lung Cancer Conference™ Medical Crossfire® Case DiscussionMay 31, 20163.75
Rapid Summaries and Commentaries: Update from Chicago - Advances in the Treatment of Lung CancerJun 09, 20162.5